Structured evidence table for Rooibos Cardiometabolic Randomized Trial, generated from 1 reusable source document in the Migaku knowledge base.
| topic | claim | evidence level | citation | source |
|---|---|---|---|---|
| Rooibos Cardiometabolic Randomized Trial | Elderly patients and patients with comorbidity disorders including pulmonary disease, cardiac disease, kidney disease, diabetes, and hypertension have been associated with greater mortality rates, suggesting highly susceptible and/or vulnerable groups within the infected population (,). | 3 | Sheik Abdul Naeem (2021) | Rooibos, a supportive role to play during the COVID-19 pandemic? |
| Rooibos Cardiometabolic Randomized Trial | Consequently, it had been hypothesised that diabetes and hypertension treatment with ACE2-stimulating drugs increases the risk of developing severe and fatal COVID-19 (,). | 3 | Sheik Abdul Naeem (2021) | Rooibos, a supportive role to play during the COVID-19 pandemic? |
| Rooibos Cardiometabolic Randomized Trial | Furthermore, there is some evidence to demonstrate that treatment with ACEIs or ARBs can decrease the severity of pulmonary injury by SARS-CoV-2, with preclinical data suggesting a potential mechanism of benefit (). | 3 | Sheik Abdul Naeem (2021) | Rooibos, a supportive role to play during the COVID-19 pandemic? |
| Rooibos Cardiometabolic Randomized Trial | Lewnard and Lo, 2020 Fang et al., 2020 Emanuel et al., 2020 Shi et al., 2020 Patel and Verma, 2020 Rodriguez-Morales et al., 2020 The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for the current Coronavirus disease 2019 (COVID-19) pandemic. | 3 | Sheik Abdul Naeem (2021) | Rooibos, a supportive role to play during the COVID-19 pandemic? |
Source documents